3Bryan BB,Schnitt SJ,Collins LC.Ductal carcinoma in situ with basal-like phenotype:a possible precursor to invasive basal-like breast cancer[J].Mod Pathol,2006,19(5):617-621.
4Goldhirsch A,Wood WC,Coates AS,et al.Strategies for subtypes dealing with the diversity of breast cancer:highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J].Ann Oncol,2011,22(8):1736-1747.
5Siziopikou K,Cobleigh M.The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies[J].Breast,2007(16):104-107.
6DENT R,TRUDEAU M,PRITCHARD KI,et al.Triple negative breast cancer:clinical features and patterns of recurrence[J].Clin Cancer Res,2007,13(15):4429-4434.
7WU J,LI S,JIA W,et al.Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triplenegative breast cancer[J].J Cancer Res Clin Oncol,2011,137(10):1505-1510.
8Kashiwagi S,Yashiro M,Takashima T,et al.Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at StageⅡ:usefulness of prognostic markers E-cadherin and Ki67[J].Breast Cancer Res,2011,13(6):122.
9Perez EA,Patel T,Moreno-Aspitia A.Efficacy of ixabepilone in ER/PR/HER2-negative(triple-negative)breast cancer[J].Breast Cancer Res Treat,2010,121(2):261-271.
10Liedtke C,Mazouni C,Hess KR,et a1.Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J].J Clin Oncol,2008(26):1275-1281.
